Immunotherapy Industry, November 2014 Market Reports from Top Publishers

You might be interested in: Therapeutics, Cancer, Medical Equipment, more »


 
1-10 of 45 reports for Immunotherapy

Genitope Corporation (GTOP) - Strategic SWOT Analysis Review

Genitope Corporation (GTOP) - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Amplification helps development of personalized active immunotherapies. Genitope help patients who are diagnosed with b-cell malignancies. The company is headquartered in california, the us ...

Biotec Pharmacon ASA (Symbol:BIOTEC) SWOT Analysis, Strategy, Revenues and Profits

Biotec Pharmacon ASA (Symbol:BIOTEC) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Including immunotherapy of cancer, general infection prophylaxis, and imbalanced immune responses. Biotec pharmacon is headquartered in tromso, norway.Biotec pharmacon asa key recent developments ...

Opexa Therapeutics, Inc. (Symbol:OPXA) SWOT Analysis, Strategy, Revenues and Profits

Opexa Therapeutics, Inc. (Symbol:OPXA) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Which is a personalized t-cell immunotherapy in a phase iib clinical development program for the treatment of secondary progressive multiple sclerosis. The company specializes in flow cytometry ...

Compugen Ltd. (Symbol:CGEN) SWOT Analysis, Strategy, Revenues and Profits

Compugen Ltd. (Symbol:CGEN) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Compugen ltd. Key recent developmentsoct 29, 2014: compugen reports third quarter 2014 financial resultsoct 14, 2014: compugen achieves second preclinical milestone in cancer immunotherapy ...

Sorrento Therapeutics, Inc. (Symbol:SRNE) SWOT Analysis, Strategy, Revenues and Profits

Sorrento Therapeutics, Inc. (Symbol:SRNE) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Is headquartered in san diego, california, the us.Sorrento therapeutics, inc. Key recent developmentsaug 26, 2014: sorrento awarded nih grant to advance immunotherapy targeting idiopathic pulmonary ...

Oncothyreon Inc. (ONTY) - Financial and Strategic SWOT Analysis Review

Oncothyreon Inc. (ONTY) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Ont-10 and tecemotide constitute to oncothyreon s antigen- specific immunotherapy platform. It also focuses on clinical development and market commercialization of its pipeline programs. The company ...

Immunotherapy in Oncology: Drug Pathway Analyzer 2014

Immunotherapy in Oncology: Drug Pathway Analyzer 2014

  • $ 3 675
  • Industry report
  • November 2014
  • by Bioseeker

... immunotherapy drug-pathway relationship by using up to four different pathway sources and further refine your analysis with up to 20 different pipeline parameters, including parameters such as presence ...

Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014

Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • October 2014
  • by Bioseeker

... Targeting immune checkpoints in cancer immunotherapy drug pipeline update 2014 bioseeker's targeting immune checkpoints in cancer immunotherapy: drug pipeline update is the most up to date ...

Immunotherapy in Oncology Drug Pipeline Update 2014

Immunotherapy in Oncology Drug Pipeline Update 2014

  • $ 3 675
  • Industry report
  • October 2014
  • by Bioseeker

... immunotherapy in oncology drug pipeline update 2014 cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity ...

Respiratory Therapy News OCTOBER 2014

Respiratory Therapy News OCTOBER 2014

  • $ 1 114
  • Industry report
  • October 2014
  • by Espicom Business Intelligence

... Industry trend analysis - j&j bolsters immunotherapy pipeline with second aduro collaborationindustry brief - fda advisory committee recommends kalydeco approvalindustry brief - ansun reports data ...

About 600 reports for Immunotherapy

Download Unlimited Documents from Trusted Public Sources

Medinet Annual Report 2013

  • Http www edgar online com
  • January 2013
    171 pages
  • Equity Market  

    Preferred Stock  

    Common Stock  

  • United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.